Shots:

• The P-lll CAN-COVID trial involves assessing Ilaris (canakinumab) + SOC vs PBO + SoC in 454 patients aged 18-98yrs. with COVID-19 pneumonia and cytokine release syndrome CRS- with its expected full results in early 2021
• Result: The trial fails to meet its 1EPs of survival without the need for mechanical ventilation up to day29 (88.8% vs 85.7%) and did not meet its 2EPs of COVID-19-related mortality up to 4 wks. (4.9% vs 7.2%)
• Canakinumab is mAb that binds to and neutralizes (IL-1β)- blocking its action. Additionally- P-III trial for ruxolitinib in COVID-19 is ongoing- with preliminary results expected by end of 2020

­ Ref: Novartis | Image: Novartis